Climb Bio (NASDAQ:CLYM – Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Climb Bio Price Performance
Shares of CLYM stock opened at $1.27 on Wednesday. The business has a fifty day simple moving average of $1.27. Climb Bio has a 52-week low of $1.05 and a 52-week high of $9.58. The stock has a market cap of $85.82 million, a price-to-earnings ratio of -0.60 and a beta of -0.12.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
- Five stocks we like better than Climb Bio
- Trading Halts Explained
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- What Are Dividend Achievers? An Introduction
- Why Boeing May Be Ready to Take Off After Latest Developments
- Using the MarketBeat Stock Split Calculator
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
